The aim of this article was to review the association between androgen deprivation therapy (ADT) and the risk of stroke in patients with prostate cancer (PC). Thus, we performed this study to understand the impact of ADT on the incidence of stroke in PC patients.
Arousal incontinence (AI) occurs during physical or psychological sexual stimulation in men and has been described after radical prostatectomy (RP). The goals of this study are to describe the characteristics of men experiencing AI, outline the nature of their symptoms, and assess for predictors of this condition.
Penile cancer is known for its aggressive nature and propensity for loco-regional metastases. It is recognized by its stepwise regional spread to the inguinal and pelvic lymph nodes (LNs) before progressing to metastatic disease. Thus, the extent of lymphatic involvement remains the most important predictor of survival. Due to the rarity of the disease, high-level […]
Ferring launches new company FerGene, with a focus on the global development and US commercialization of nadofaragene firadenovec, for high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer patients Blackstone Life Sciences will invest $400 million USD and their expertise to accelerate the future development and commercialization of nadofaragene firadenovec, an investigational gene therapy The FDA […]
{{header-clinical-trials-navigation}} Fluciclovine (FACBC) PET/CT Site-Directed Therapy of Oligometastatic Prostate Cancer (Flu-BLAST-PC) Condition: Prostate Adenocarcinoma, PSA Level Greater Than or Equal to 0.5, PSA Level Less Than Ten Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04175431 Sponsor: University of Washington Phase: Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: Patient […]
Introduction: Metastatic renal cell carcinoma (mRCC) in recent years has been one of the diseases in the oncology that has experienced the greatest development of targeted therapies.Area covered: On one hand, more and more refined acquisitions of molecular biology are allowing a better sub-classification of this tumor, identifying new and peculiar biological profiles of patients […]
Nivolumab is a standard treatment for previously treated advanced renal-cell carcinoma. However, nivolumab is effective in only a limited number of patients; therefore, we evaluated the prognostic value of several biomarkers, including inflammation-based prognostic scores and changes in these scores following nivolumab treatment in Japanese patients with metastatic renal-cell carcinoma.
Kidney cancers represent 2% of cancers worldwide; the most common type is renal clear cell carcinoma (RCC). Surgical treatment remains the only effective therapy for localized renal cell carcinoma. Approximately 20% to 38% of patients undergoing radical nephrectomy (RN) for localized RCC will have subsequent disease progression, with 0.
Non-muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology.
According to (inter-)national guidelines, (neo-)adjuvant and concurrent androgen deprivation therapy (ADT) in combination with external beam radiotherapy (EBRT) is optional for intermediate-risk prostate cancer (PCa) patients and is the recommended standard treatment for high-risk PCa patients.
